News | April 11, 2024
Asahi Kasei Bioprocess and Axolabs partner to accelerate oligonucleotide therapeutics development
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
JB Chemicals will pay Rs 125 crore to Novartis to license the same drug portfolio for the Indian market
The companies plan to start a pivotal Phase 3 trial in the coming months
The requirement of blood in India is estimated to be 8.5 million to 10 million units/per year, whereas the available supply is only 7.4 million units/per year
Themis Medicare’s VIRALEX is an effective and safe drug for management of mild to moderate COVID and other acute viral respiratory infections.
Viralex (Inosine Pranobex) is an immunomodulatory agent with broad-spectrum antiviral properties
Viralex is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body's defence response to viral infections
The researchers are of the view that the new drug designing strategy demonstrated by them could also be adopted to treat retroviral infections.
The rise in cases amongst the young is a cause for concern. A few specialists gave us a perspective on the issue
Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old
Subscribe To Our Newsletter & Stay Updated
